氯己定葡萄糖酸盐口咽和鼻咽去污染在肺癌手术中的随机临床试验
这项多中心平行组随机双盲安慰剂对照试验纳入474例计划行肺癌解剖性肺切除的连续成人患者,最终450例纳入改良意向性分析(氯己定组226例,安慰剂组224例)。围手术期去污染方案为口咽漱口液(0.12%氯己定)和鼻咽皂(4%氯己定)或安慰剂。主要终点术后需要有创和/或无机通气的比例在两组间无显著差异(氯己定组14.2% vs 安慰剂组15.2%;RR 0.93;95%CI 0.59-1.45;P=0.76),呼吸道医疗相关感染比例亦无差异(氯己定组13.7% vs 安慰剂组12.9%;RR 1.06;95%CI 0.66-1.69;P=0.81)。氯己定组菌血症、手术部位感染和总体金黄色葡萄球菌感染发生率显著降低,但住院时长、气管微生物群变化、术后抗生素使用和90天结局无显著组间差异。
要点
- 氯己定组术后需要有创和/或无机通气的比例为14.2%,安慰剂组为15.2%,RR 0.93(95%CI 0.59-1.45;P=0.76),无显著差异。
- 氯己定组呼吸道医疗相关感染比例为13.7%,安慰剂组为12.9%,RR 1.06(95%CI 0.66-1.69;P=0.81),无显著差异。
- 氯己定组菌血症、手术部位感染和总体金黄色葡萄球菌感染发生率显著降低。
- 两组住院时长、气管微生物群变化、术后抗生素使用和90天结局无显著差异。
适用人群与场景
- 计划行肺癌解剖性肺切除的连续成人患者。
处置流程与药物剂量
- 围手术期去污染方案:口咽漱口液(0.12%氯己定)和鼻咽皂(4%氯己定)或安慰剂。
研究设计与关键结果
- 多中心平行组随机双盲安慰剂对照试验,2012年7月至2015年4月随机474例,24例取消手术或撤回知情同意,450例纳入改良意向性分析:氯己定组226例,安慰剂组224例。
- 主要终点术后需要有创和/或无机通气的比例:氯己定组14.2% vs 安慰剂组15.2%,RR 0.93(95%CI 0.59-1.45;P=0.76),无显著差异。
- 呼吸道医疗相关感染比例:氯己定组13.7% vs 安慰剂组12.9%,RR 1.06(95%CI 0.66-1.69;P=0.81),无显著差异。
- 氯己定组菌血症、手术部位感染和总体金黄色葡萄球菌感染发生率显著降低。
- 住院时长、气管微生物群变化、术后抗生素使用和90天结局无显著组间差异。
证据类型、等级与局限
- 证据类型:多中心平行组随机双盲安慰剂对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 氯己定口咽和鼻咽去污染未减少肺癌手术后机械通气需求或呼吸道感染,不改变术后抗生素使用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Respiratory complications are the leading causes of morbidity and mortality after lung cancer surgery. We hypothesized that oropharyngeal and nasopharyngeal decontamination with chlorhexidine gluconate (CHG) would be an effective method to reduce these complications as reported in cardiac surgery.
METHODS: In this multicenter parallel-group randomized double-blind placebo-controlled trial, we enrolled consecutive adults scheduled for anatomical pulmonary resection for lung cancer. Perioperative decontamination consisted in oropharyngeal rinse solution (0.12% CHG) and nasopharyngeal soap (4% CHG) or a placebo. The primary outcome measure was the proportion of patients requiring postoperative invasive and/or noninvasive mechanical ventilation (MV). Secondary outcome measures included occurrence of respiratory and non-respiratory healthcare-associated infections (HAIs) and outcomes within 90 days.
RESULTS: Between July 2012 and April 2015, 474 patients were randomized. Of them, 24 had their surgical procedure cancelled or withdrew consent. The remaining 450 patients were included in a modified intention-to-treat analysis: 226 were allocated to CHG and 224 to the placebo. Proportions of patients requiring postoperative MV were not significantly different [CHG 14.2%; placebo 15.2%; relative risks (RRs) 0.93; 95% confidence interval (CI) 0.59-1.45; P = 0.76]. Neither of the proportions of patients with respiratory HAIs were different (CHG 13.7%; placebo 12.9%; RRs 1.06; 95% CI 0.66-1.69; P = 0.81). The CHG group had significantly decreased incidence of bacteremia, surgical-site infection and overall Staphylococcus aureus infections. However, there were no significant between-group differences for hospital stay length, change in tracheal microbiota, postoperative antibiotic utilization and outcomes by day 90.
CONCLUSIONS: CHG decontamination decreased neither MV requirements nor respiratory infections after lung cancer surgery. Additionally, CHG did not change tracheal microbiota or postoperative antibiotic utilization.
TRIAL REGISTRATION: This study is registered on ClinicalTrials.gov, number NCT01613365.
参考来源
- D'Journo XB, Falcoz PE, Alifano M, et al. Oropharyngeal and nasopharyngeal decontamination with chlorhexidine gluconate in lung cancer surgery: a randomized clinical trial. Intensive Care Med. 2018. PMID: 29671041. doi:10.1007/s00134-018-5156-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。